Eclipsebio acquired Terrain Bio to add machine‑learning RNA design and analytics to its sequencing‑first RNA genomics stack. Eclipsebio said the deal accelerates its plan to offer an end‑to‑end platform that designs RNA constructs, measures structure and translation, and informs manufacturing robustness and quality‑by‑design. CEO Peter Chu framed the acquisition as a complement between Terrain’s AI design capabilities and Eclipsebio’s high‑resolution sequencing validation. Financial terms were not disclosed. The move underscores continued consolidation among firms building integrated computational and wet‑lab platforms for RNA therapeutic discovery and GMP translation.